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Abstract: This study evaluated the properties of endogenous nitric oxide synthases (NOS) and annexin-A1 (ANXA1) 
and determined how they can be exploited in the N-methyl-N-nitro-N-nitrosoguanidine (MNNG)-induced gastric car-
cinogenesis and myenteric denervation model. Male Wistar rats were treated with MNNG and/or aminoguanidine 
(AG) for 20 weeks. In another set of experiments, rats with nondenervated and denervated stomachs were treated 
with MNNG or water for 28 weeks. Fragments of the pyloric region were processed for histopathology, NOS activity, 
and immunohistochemistry to explore the activity and expression of constitutive (cNOS) and inducible (iNOS) NO 
synthase and their relationship with annexin-A1 (ANXA1) expression. NO inhibition by AG increased the percentage 
of animals with adenocarcinomas (~29%) compared with the untreated MNNG group (~4%). Myenteric denervation 
did not alter NOS activity. cNOS activity was significantly greater in nondernervated and denervated stomachs with 
or without lesions (P<0.001) than iNOS activity (P<0.01), as confirmed by immunohistochemistry. Further, cNOS 
activity in normal stomachs and outside the lesion area was considerably higher than inside it (P<0.01). By densi-
tometric analysis of nondenervated and denervated stomachs, ANXA1 expression was modulated in epithelial and 
inflammatory cells (mast cells and neutrophils), wherein significant alterations were induced by lesion development 
and myenteric denervation. In conclusion, NO protects against the development of gastric adenocarcinomas. The 
pattern of ANXA1 expression was not associated with NOS activity or expression, suggesting that NO and ANXA1 act 
in gastric tumors in disparate pathways.
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Introduction
Inflammation is a critical component in the pro-
gression of cancer. Several cancers arise from 
sites of infection, chronic irritation, and inflam-
mation [1-4]. Nitric oxide (NO) and annexin A1 
(ANXA1) are believed to regulate many of the 
pathophysiological processes that link inflam-
mation to cancer development and progres-
sion. NO and ANXA1 have protumor and antitu-
mor effects [5, 6].
Nitric oxide (NO) is a small, short-lived biomol-
ecule that functions as a signaling molecule in 
development, immunity, and carcinogenesis. 
NO is a product of the conversion of L-arginine 
into L-citrulline by nitric oxide synthase (NOS). 
NOS has three isoforms: type 1 (neuronal or 
brain NOS; nNOS) and type 3 (endothelial NOS; 
eNOS) are Ca2+-dependent and constitutively 
expressed (cNOS), generated primarily by neu-
rons and endothelial cells, respectively; type 2 
NOS (macrophage or inducible NOS; iNOS) is 
Ca2+-independent and is induced in various cell 
types by inflammatory cytokines, lipopolysac-
charides, and other stimuli. The NOS isoforms 
are tissue-specific, and their expression pat-
tern can be altered under pathological condi-
tions [7-9]. eNOS and nNOS exist in the stom-
ach, and although iNOS is not detected in 
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normal gastric tissues, it is significantly induced 
on exposure to endotoxin.
In certain tumor tissues, NO enhances tumor 
angiogenesis and induces vasodilatation, thus 
accelerating tumor growth. Other tumors, 
including gastric and colon cancers, express 
less NOS than normal tissue by immunohisto-
chemistry, and there is a link between the loss 
of NO and carcinogenesis [10]. Further, NO 
mediates tumoricidal activity in vivo, as demon-
strated using sodium nitroprusside, a genera-
tor of NO that inhibits MNNG-induced gastric 
carcinogenesis [11].
ANXA1, a 37-kDa protein that binds calcium 
and phospholipids binding, is an anti-inflamma-
tory mediator, regulating leukocyte migration, 
cell proliferation and death signaling, apopto-
sis, and carcinogenesis [12]. ANXA1 expression 
is reduced in certain cancers but increased in 
other cancer types. Many clinical tumor cases 
report that the loss of ANXA1 contributes to 
cancer cell resistance to apoptosis and impli-
cate it as a negative biomarker in cancer devel-
opment and progression [12].
The enteric nervous system can be exploited in 
carcinogenesis, especially in gastric tumors. 
Available human and animal data have shown 
that intrinsic denervation is protective against 
the development of tumors, but the reasons for 
this protection remain unknown [13-16]. As the 
NO and ANXA1 regulate many of the pathophys-
iological processes that link inflammation to 
cancer development and progression with pro-
tumor and antitumor effects, we examined the 
effects of inhibiting NO production on the inci-
dence of gastric tumors that are induced by 
N-methyl-N-nitro-N-nitrosoguanidine (MNNG), 
the activity and expression of cNOS and iNOS in 
nondenervated and denervated rat stomachs 
with and without tumors, and the relationship 
between NOS activity and ANXA1 expression.
Materials and methods
Animals
Male Wistar rats, weighing 100–150 g at the 
beginning of the experiment, were provided by 
the Central Animal House, Ribeirão Preto 
School of Medicine and maintained in the 
Animal Facilities of the Department of 
Pathology. The animals were housed in plastic 
cages (4 animals/cage) under a 12-hour 
light/12-hour dark cycle in rooms with natural 
ventilation at 24 ± 2°C and received a standard 
maintenance diet (Nuvilab-CR-Nuvital Nutrients 
Prodvet Ltda., Brazil) and tap water ad libitum. 
The experiments were performed per the 
Committee on Care and Uses of Laboratory 
Animals of the National Research Council, NIH 
(USA) and the Ethics Committee for Animal 
Experimentation (CEEA) of FAMERP (Protocol 
6193/2008), São José do Rio Preto, SP.
Experimental design
To determine the effects of inhibiting NO pro-
duction on the incidence of MNNG-induced 
gastric tumors, four experimental groups were 
evaluated: in MNNG Group (n = 38), animals 
ingested a solution of MNNG (Aldrich Chemical 
Co., Inc., Milwaukee, WI) in distilled and deion-
ized water at 100 mg/L [13]; MNNG+AG Group 
(n = 38) animals ingested MNNG and amino-
guanidine (AG – 50 mg/Kg/day) [17]; AG Group 
(n = 20) ingested distilled and deionized water 
and AG at the same concentration as in 
MNNG+AG Group; and Control Group (n = 12) 
animals ingested distilled and deionized water. 
All animals were weighed weekly, and fluid 
intake (MNNG or MNNG plus AG; water plus AG 
or water) and survival rate was measured daily. 
After 20 weeks, the animals were sacrificed; 
the first adenocarcinoma was detected at this 
time point. The macroscopic analysis of stom-
achs was performed to detected tumor inci-
dence and morphology.
To investigate the relationship between intrin-
sic denervation, NOS activity and ANXA1 
expression another set of experiments was per-
formed. Four experimental groups were evalu-
ated: Nondenervated (ND) and Denervated (D) 
Groups (n = 5/ group) animals ingested distilled 
and deionized water; ND+MNNG and D+MNNG 
(n = 10/group), with MNNG-induced gastric 
lesions.
For myenteric denervation, male Wistar rats, 
weighing 100–150 g, were anesthetized i.m. 
with ketamine hydrochloride and thiazine chlo-
ride (0.15 ml/0.05 ml/100 g of weight). Each 
stomach was exteriorized by midline upper 
abdominal laparotomy and isolated from the 
peritoneal cavity through a small fenestration 
in a plastic sheet for topical application of 0.6% 
benzalkonium chloride (BAC; v/v, Aldrich 
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Chemical Co.; diluted in saline). The isolated 
stomachs were wrapped with gauze that was 
soaked in BAC or saline and kept moist for 30 
min. The serosal surface of the stomachs was 
washed thoroughly with saline, the organs were 
returned to the abdominal cavity, and the 
abdominal wall was sutured. Treatment with 
BAC was effective, leading to a decrease of 
approximately 45% of the population of myen-
teric neurons [13].
Sixteen weeks after surgery, the animals in 
ND+MNNG and D+MNNG Groups ingested a 
solution of MNNG in distilled and deionized 
water (100 mg/L) for 28 weeks. The animals 
were sacrificed 2 months after the final intake 
of MNNG, and the stomachs were harvested for 
histopathological analysis, NOS activity assay, 
and immunohistochemistry. 
Macroscopic and histopathological analysis
After sacrifice, the stomachs were removed, 
opened along the greater curvature, rinsed with 
saline solution, and examined for the presence 
of tumors. Fragments of the pyloric region of 
the stomach (antrum) were fixed in 4% buffered 
formalin for 12 h, washed in tap water, dehy-
drated in an ethanol series, and embedded in 
paraffin. The gastric antrum was analyzed in 
4-μm sections that were stained with hematox-
ylin-eosin and toluidine blue 0.5%; the lesions 
were classified as benign or malignant, based 
on the general classification of the epithelial 
lesions.
Assay for NOS activity
NOS (cNOS and iNOS) activity was measured 
inside and outside of tumors of nondenervated 
and denervated stomachs (n = 10 fragments of 
the pyloric region per group). The full thickness 
of pyloric gastric wall was collected and frozen 
at -70°C until they were processed for NOS 
activity, as described [18, 19].
Briefly, tissue was homogenized and centri-
fuged at 100,000 g for 10 min at 4°C. 
Supernatants were assayed for NOS activity by 
measuring the conversion of L-[14C]-arginine to 
[14C]-citrulline, as described, except that the 
incubation was performed at room tempera-
ture for 60 min. The protein content of the 
supernatant was measured using Coomassie 
blue per the manufacturer’s recommendations 
(Coomassie Blue Reagent; Pierce Chemical, 
Rockford, IL). NOS activity was expressed in 
picomoles of citrulline per milligram of protein 
per hour (pmol/mg protein/hour). 
Immunohistochemistry
Immunohistochemistry was performed using 
streptavidin-peroxidase (SP) and polyclonal 
antibodies against iNOS, eNOS, nNOS (Santa 
Cruz Biotechnology, USA), and ANXA1 (Zymed 
Laboratories, Cambridge, UK). Deparaffinized 
sections were incubated in citrate buffer, pH 
6.0 at 96°C for 20 min in a pressure cooker to 
retrieve antigens, washed 3 times with distilled 
water, and incubated with 3% hydrogen perox-
ide for 30 min in methanol to block endogenous 
peroxidase activity.
After being washed 3 times with phosphate-
buffered saline (PBS, pH 7.4), the sections were 
blocked with 10% goat serum for 15 min to 
reduce nonspecific binding and incubated with 
rabbit polyclonal anti-iNOS, eNOS, nNOS 
(1:100), or anti-ANXA1 (1:1000) in 2% bovine 
serum albumin (BSA) at 4°C overnight. The sec-
tions were washed 3 times with PBS, incubated 
with the universal LSABTM2 Kit/HRP second-
ary antibody (DAKO, USA) per the manufactur-
er’s protocol, washed 3 times with PBS, and 
developed with 3,3 0-diaminobenzidine (DAKO). 
At the end of the reaction, the sections were 
washed thoroughly in distilled water, counter-
stained with hematoxylin, and mounted on 
glass slides. As a control, some sections were 
incubated with 2% BSA, without primary 
antibody.
ANXA1 immunostaining was quantified by den-
sitometric analysis on an arbitrary scale from 0 
to 255 with AxioVision software on a Zeiss-
Axioskop II light microscope, and the data were 
expressed as mean ± standard error (SE).
Data analysis
For survival rate and tumor incidence, data are 
reported as mean ± SEM and were submitted 
to the test of proportions, normal approxima-
tion for the difference in the percentage of ani-
mals with tumors, to Student´ s t-test and one-
way analysis of variance (ANOVA), and then to 
the Tukey–Kramer multiple comparisons test. 
The proportions were considered distinct when 
the observed z was greater than the critical z. 
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Differences with values of P<0.05 were consid-
ered significant. For densitometric analysis, 
statistical differences between groups were 
determined by Student´ s t test and one-way 
analysis of variance (ANOVA) and, if significant, 
followed by Bonferroni test. In all cases, a prob-
ability value < 0.05 was considered significant.
Results
Effects of inhibition of NO production on 
MNNG-induced gastric tumors
Sixty-three percent of the animals in MNNG 
Group (treated with MNNG) and 55% of 
MNNG+AG Group (treated with MNNG and ami-
noguanidine - AG) survived the experimental 
period (20 weeks), versus 100% of animals in 
AG and Control Groups that remained in good 
overall health. On initial consumption of the 
carcinogen, there were no differences in body 
weight or fluid ingestion between groups. After 
several weeks, body weight and liquid diet 
intake declined significantly in the groups that 
received MNNG compared with animals that 
received only water or water plus AG. Only ani-
mals that were treated with MNNG developed 
adenocarcinomas in the antrum. The tumors 
were raised, with a wide base and sessile or 
ulcerated lesions (Figure 1A-C). Morphologically, 
there were no differences between lesions in 
the groups that were treated with MNNG. 
Histologically, all tumors were adenocarcino-
mas (Figure 1D and 1E). The first adenocarci-
noma was detected 20 weeks after MNNG was 
first ingested. The MNNG + AG Group had more 
Figure 1. Effect of aminoguanidine on MNNG-induced gastric carcinogenesis. Macroscopic analysis of stomachs 
after treatment with MNNG (A), MNNG plus aminoguanidine (MNNG+AG; B), and water (Control; C). Raised le-
sions (arrows). Bars: 10 mm. Histopathological analysis of adenocarcinomas in animals treated with MNNG (D) and 
MNNG+AG (E). Stain: hematoxylin & eosin. Bars: 50 µm. 
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animals with tumors (28.57%) compared with 
MNNG Group (4.16%) according z test.
NOS activity in gastric tissue
Myenteric denervation did not alter NOS activi-
ty in gastric tissues without lesions (ND and D 
Groups) (Figure 2A), which was mediated pri-
marily by cNOS. The generation of L-citrulline 
from cNOS in normal gastric tissue (ND and D 
Groups) and outside the tumoral area 
(ND+MNNG and D+MNNG Groups) was consid-
erably higher than inside the tumor (Figure 2B 
and 2C). As in ND and D Groups, iNOS levels 
were low in gastric tissues with lesions (inside 
or outside the tumor) of ND+MNNG and 
D+MNNG Groups (Figure 2B and 2C).
NOS expression in gastric tissue
By immunohistochemical analysis of the gas-
tric antrum, myenteric denervation did not alter 
NOS expression in nondenervated or denervat-
ed stomachs confirming the NOS assay data. 
All normal gastric mucosa samples (ND and D 
Groups) and tumor tissues (ND+MNNG and 
D+MNNG Groups) were immunoreactive for 
nNOS and eNOS (Figure 3A-C and 3E-G). nNOS 
was highly expressed in epithelial cells (Figure 
3C and 3G), muscle, and the myenteric plexus, 
and eNOS was detected in endothelial cells 
(Figure 3B and 3F). iNOS was undetected by 
immunohistochemistry in normal and gastric 
tumor tissues (Figure 3D and 3H).
ANXA1 expression in gastric tissue
ANXA1 immunoreactivity was analyzed in all 
experimental groups (ND; D; ND+MNNG; 
D+MNNG) and was detected in epithelial and 
inflammatory cells, primarily mast cells and 
neutrophils. Epithelial cells in the stomachs of 
D Group expressed low levels of ANXA1 com-
pared with ND Group. Development of adeno-
carcinomas in the stomachs of ND+MNNG 
Group was associated with lower ANXA1 immu-
noreactivity in the epithelium compared with 
ND Group, whereas adenocarcinomas from the 
stomachs of D+MNNG Group stained robustly 
for ANXA1 versus D Group (Figure 4A and 4B). 
No signal was detected in the control sections 
(Figure 4C). Densitometric analysis of the epi-
thelial cells confirmed the morphological find-
ings, demonstrating significant modulation of 
ANXA1 under various experimental conditions 
(Figure 4D).
As in epithelial cells, inflammatory cells (mast 
cells and neutrophils) from denervated stom-
achs expressed low levels of ANXA1 in their 
cytoplasm compared with those from nonde-
nervated stomachs. The development of 
lesions in nondenervated stomachs (ND+MNNG 
Group) was associated with lower ANXA1 immu-
noreactivity in mast cells (Figure 5A), whereas 
Figure 2. Measurement of total NOS (tNOS) activ-
ity in fragments of nondenervated (ND) and dener-
vated (D) stomachs without lesions and with lesions 
(ND+MNNG and D+MNNG Groups, respectively). 
Data are mean ± SE of [14C]-citrulline generation 
and expressed as pmol/mg protein/hour (n = 10 
fragments per group). iNOS activity was lower than 
cNOS in all experimental groups (A-C). No differences 
in NOS activity were detected after myenteric dener-
vation (A, ND and D Groups, * P<0.001). The cNOS 
activity inside tumors (in; ND+MMG and D+MNNG 
Groups) was significantly lower than in ND and D 
stomachs (* P < 0.001) and outside tumors (out; 
ND+MNNG Group, * P<0.01; D+MNNG Group, * P < 
0.001) (B and C). 
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neutrophils presented an increase in ANXA1 
levels compared with cells from ND Group 
(Figure 5D).
In denervated stomachs (D+MNNG Group), no 
differences in ANXA1 expression was noted in 
these inflammatory cells.
The densitometric analysis confirmed the mod-
ulation of ANXA1 expression in inflammatory 
cells, as shown in Figure 5C (mast cells) and 5F 
(neutrophils). Toluidine blue-stained histologi-
cal sections confirmed that the immunostained 
cells were mast cells (Figure 5B) and neutro-
phils (Figure 5E).
Discussion
In MNNG-induced gastric carcinogenesis, we 
demonstrate that NOS activity inhibits the 
development of gastric lesions through treat-
ment with AG. We find that the anti-inflammato-
ry mediator NO and ANXA1 have disparate 
functions in the progression of gastric cancer. 
By immunohistochemistry of NOS and ANXA1 
in the stomachs on chemical denervation and 
treatment with MNNG, we confirmed the pres-
ence of constitutive NOS (cNOS) and the modu-
lation of ANXA1 in various cell types that regu-
late tumor development.
Initially, to confirm the protective effect of 
endogenous NO on tumor development, ani-
mals were treated with MNNG and AG, a NOS 
inhibitor, for 20 weeks. AG increased the num-
ber of animals with adenocarcinomas, indicat-
ing that inhibition of NO synthesis accelerates 
MNNG-induced gastric carcinogenesis in rats. 
That we did not observe iNOS by citrulline assay 
or immunohistochemistry suggests that AG 
blocks the cNOS isoform. Despite being a 
selective inhibitor of iNOS with a 50- to 500-
fold higher affinity [20], AG also suppresses 
cNOS activity by the alteration of its prosthetic 
heme moiety in a time- and metabolism-depen-
dent manner that could be attenuated by the 
presence of the natural substrate, L-arginine 
[21].
Figure 3. NOS immunostaining in nondenervated (ND) stomachs. Normal gastric mucosa (ND Group; A) and adeno-
carcinoma (ND+MNNG Group; E) showing eNOS expression in endothelial cells (arrows; B and F – squared area 
of figures A and E, respectively) and nNOS expression in epithelial cells (arrows; C and G). No immunoreactivity for 
iNOS was observed in normal and tumor tissues (D and H). Counterstain: hematoxylin. Bars: 10 µm. 
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NO has been demonstrated to mediate tumori-
cidal activity using sodium nitroprusside, and it 
has been suggested that this effect is related 
to the suppression of antral epithelial prolifera-
tion [11]. Thus, the reduced expression of NOS 
in stomach tumors and the absence of iNOS, 
consequently decreasing NO production, might 
accelerated the pathogenesis and mainte-
nance of cancer [7].
We examined the effects of myenteric denerva-
tion on NOS activity in gastric tissues. 
Compared with iNOS, cNOS had higher activity 
in nondenervated and denervated stomachs, 
but no differences in the generation of 
L-citruline were observed between groups. 
Similarly, nondenervated and denervated stom-
achs that were treated with MNNG experienced 
increased cNOS activity in extratumoral tissues 
versus those inside tumors, suggesting that 
decreased NOS activity was linked to tumor 
development.
We complemented these functional data by 
measuring cNOS and iNOS expression in nor-
mal tissues and stomach lesions. Both iso-
forms of cNOS, eNOS and nNOS, were detected 
in these tissues, whereas iNOS was not 
expressed, confirming the NOS assay. These 
findings are consistent with data on normal and 
cancerous human gastric tissues [22], wherein 
the expression of cNOS isoforms in stomach 
tumors was significantly lower than in normal 
stomach mucosa, whereas iNOS expression in 
tumor tissues was significantly lower versus 
cNOS expression.
Our study suggests that lesion development is 
associated with a reduction in cNOS activity 
that is not influenced by myenteric denervation. 
The mechanisms by which NOS expression 
declines in tumor tissues are unknown; identi-
fying them could increase our understanding of 
carcinogenesis. Nishio and colleagues [23] 
suggested that endogenous NO that is derived 
from both cNOS and iNOS regulates mucosal 
defense in the inflamed stomach, in part by 
decreasing acid secretion, and maintains 
mucosal integrity under such conditions. 
The glucocorticoid-modulated ANXA1 downreg-
ulates leukocyte extravasation and the release 
of inflammatory mediators by directly inhibiting 
cytosolic phospholipase A2 and the expression 
of inducible cyclooxygenase and NOS [24]. 
Alterations in ANXA1 expression occur in many 
tumors, rising in pancreatic, hepatic, and 
esophageal and esophagogastric junction ade-
nocarcinomas, but declining in esophageal, 
prostate, thyroid, and nasopharyngeal carcino-
mas [25, 26]. Further, ANXA1 is a critical medi-
ator of apoptosis and a substrate receptor for 
epidermal growth factor [27, 28]. Thus, we 
examined ANXA1 expression in gastric tissues 
and its relationship with NOS activity and myen-
teric denervation in the MNNG-induced carci-
nogenesis model.
Under all experimental conditions, nondener-
vated and denervated stomachs with or with-
out adenocarcinomas were positive for ANXA1 
in the epithelium and inflammatory cells, par-
ticularly mast cells and neutrophils, confirming 
Figure 4. ANXA1 expression in epithelial cells of denervated stomachs without or with lesions (D and D+MNNG 
Groups, respectively). Strong ANXA1 immunoreactivity in epithelial cells from gastric lesions (arrows; B) compared 
with cells of D Group (arrows; A). Control of reaction (C). Counterstain: hematoxylin. Bars: 10 µm. (D) Densitomet-
ric analysis of epithelial cells immunostained for ANXA1 in nondenervated (ND), denervated (D), ND+MNNG and 
D+MNNG Groups. Values (arbitrary units) are expressed as mean ± SE of sections analyzed from 5 rats/ group. * P 
<0.001 versus ND Group; # P <0.001 versus D and ND+MNNG Groups.
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previous data [29-31]. Myenteric denervation 
significantly decreased ANXA1 levels in the epi-
thelium compared with nondenervated stom-
achs. ANXA1 has antiproliferative effects in 
epithelial cells [32], and its expression 
increased in epithelial cells of human nasal pol-
yps on treatment with glucocorticoids [30]. 
Further, increased activity of the ANXA1 pro-
moter in lung epithelial cells is linked to cellular 
activation in the control of the local and sys-
temic responses that are induced by lipopoly-
saccharide in mice [33]. Thus, reduced expres-
sion of ANXA1 in the epithelium of denervated 
stomachs suggests its impaired activation 
compared with the gastric epithelium of nonde-
nervated stomachs.
The development of epithelial lesions in nonde-
nervated stomachs caused a significant 
decrease in ANXA1 in the epithelium compared 
with nondenervated stomachs without lesions, 
whereas it increased in denervated stomachs 
with adenocarcinomas compared with dener-
vated stomachs without lesions.
Studies involving 1072 patients with gastric 
cancer reported that loss of ANXA1 expression 
was significantly associated with lymph node 
metastasis, advanced disease stage, and poor 
histological differentiation [26], indicating an 
effect of reduced ANXA1 levels in disease pro-
gression. The function of ANXA1 in tumor pro-
gression was determined in prostate cancer 
cells in vitro, in which ANXA1 levels increased, 
reducing cell viability through the induction of 
caspase-mediated apoptosis, colony forma-
tion, and the proliferative effects of epidermal 
growth factor [34]. Likely, increases in ANXA1 
levels in denervated stomachs suppress the 
development of gastric tumors, reducing the 
number of lesions [13].
As in epithelial cells, myenteric denervation 
was associated with lower ANXA1 expression in 
mast cells and neutrophils. Despite the altered 
ANXA1 expression in denervated stomachs, no 
differences in protein levels were observed in 
inflammatory cells after tumor development. 
However, adenocarcinomas in nondenervated 
Figure 5. ANXA1 expression in inflammatory cells. Adenocarcinoma of nondenervated stomachs (ND+MNNG Group) 
with ANXA1-positive mast cells (arrows; A) and neutrophils (arrows; B). Counterstain: hematoxylin. Adjacent histo-
logical section after staining with 0.5% toluidine blue confirms that positive cells are mast cells (arrows; C) and 
neutrophils (D). Bars: 10 µm. Densitometric analysis of mast cells (E) and neutrophils (F) immunostained for ANXA1. 
Values (arbitrary units) are expressed as mean ± SE of sections analyzed from 5 rats/ group. ANXA1 levels signifi-
cantly reduced in inflammatory cells of denervated stomachs (D Group) compared with nondenervated (ND Group). 
In D+MNNG Group, diminished ANXA1 expression was detected in mast cells, whereas neutrophils exhibited a sig-
nificant increase in ANXA1 expression compared with cells of ND Group. * P < 0.001 versus ND Group.
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stomachs harbored mast cells with lower levels 
of ANXA1 versus cells in nondenervated stom-
achs without lesions.
ANXA1 expression is altered in mast cells in 
inflammatory diseases and cancer. In the tra-
chea and mesentery of rats, mast cells express 
more ANXA1 after treatment with dexametha-
sone, suggesting that glucocorticoids inhibit 
degranulating mast cells [29, 30, 35]. Similarly, 
pretreatment of mice with Ac2-26 (the 
N-terminal region of ANXA1) increases the 
number of intact mast cells in the pleural cavity 
and decreases the release of histamine in a 
model of ovalbumin-induced allergic inflamma-
tion, confirming the protective effect of ANXA1 
in their activation [36]. In head and neck 
tumors, mast cells in the stromal tumor and 
peritumoral area express high levels of ANXA1 
in their cytoplasmic granules, although the 
number of degranulated cells in these regions 
rises compared with the control [31]. In gastric 
MNNG-induced adenocarcinomas, the number 
of degranulated and intact mast cells increas-
es, especially in denervated stomachs that har-
bor phenotypically altered mast cells [37]. This 
finding, in conjunction with decreased levels of 
ANXA1, suggests that mast cell activation is 
affected through the release of mediators that 
function in tumorigenesis. However, this effect 
of ANXA1 was not associated with iNOS activity 
or expression in this gastric carcinogenesis 
model. 
Neutrophils in nondenervated stomachs with 
adenocarcinomas (ND+MNNG Group) upregu-
lated ANXA1 compared with those in nondener-
vated stomachs without lesions (ND Group). 
ANXA1, on the plasma membrane of adherent 
neutrophils, is inhibitory, reducing the extent of 
transmigration across endothelial cells [29]. 
ANXA1 mediates the apoptosis of neutrophils, 
an important mechanism of limiting the inflam-
matory response [38]. Thus, myenteric dener-
vation modulates ANXA1 levels in neutrophils 
in gastric adenocarcinomas, exacerbating the 
inflammatory response that is induced by the 
carcinogenesis.
In this context and under our experimental con-
ditions, NO protects against the development 
of gastric adenocarcinomas. Further, we exam-
ined the properties of endogenous ANXA1 and 
NOS and determined how they can be exploited 
in the MNNG-induced carcinogenesis and 
myenteric denervation model, concluding that 
they act in disparate pathways in gastric 
tumors. The molecular basis of NOS and ANXA1 
expressions and their functions in the progres-
sion of gastric cancer should be investigated in 
follow-up studies. Agents, such as activators or 
modulators of NO and ANXA1, are potentially 
novel therapeutic targets, particularly in gastric 
cancer.
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